

Lebrikizumab

We recommend lebrikizumab in AE patients who are candidates for systemic treatment.	↑↑	100% 100 % Agreement (18/18) Evidence and consensus based, see Evidence Report
---	-----------	--

lebrikizumab: in licence for ≥ 12 years of age (with bodyweight ≥ 40 kg);
dosage: initially 500 mg s.c. day 1 and 15 followed by 250 mg s.c. Q2W
At prescriber's discretion, every fourth week dosing may be considered for patients who achieve clear or almost clear skin after 16 weeks of treatment.

Certainty of evidence: Network meta-analysis from 2024^{1,2}:

Short term (up to 16 weeks) vs placebo (NMA medications used in clinical practice)

⊕⊕⊕⊕ HIGH for mean difference **POEM** -6.2 (-7.4, -5.1)

⊕⊕⊕○ MODERATE for mean difference **EASI** -8.5 (-10.4, -6.5); **DLQI** -4.7 (-6.4, -2.8)

⊕⊕○○ LOW for mean difference **peak pruritus NRS** -2.1 (-2.6, -1.7)

For lebrikizumab versus other drugs, see Evidence Report

Mechanisms of action and efficacy

Lebrikizumab is a high-affinity humanized immunoglobulin G4 mAb that binds specifically to soluble interleukin 13 and selectively prevents formation of the IL-13R α 1/IL-4R α heterodimer receptor signaling complex.

In two identically designed randomised, double-blind, placebo-controlled monotherapy phase 3 studies (ADvocate1 and ADvocate2), adolescents (aged 12 years and older) and adult AE patients received either lebrikizumab at a dose of 250 mg Q2W (loading dose of 500 mg at baseline and week 2) or placebo.³ After 16 weeks, 43.1% (lebrikizumab arm) vs. 12.7% (placebo arm) in ADvocate1 and 33.2% vs. 10.8% in ADvocate2 achieved the primary endpoint of IGA score of 0 or 1 with a reduction of at least 2 points.³ Patients who responded to lebrikizumab at the end of the 16-week induction period were re-randomized 2:2:1 to receive lebrikizumab 250 mg Q2W, Q4W or placebo (lebrikizumab withdrawal) for 36 additional weeks. After 52 weeks, an IGA of 0 or 1 with a ≥ 2 point improvement was maintained by 71.2% and 76.9% of patients treated with lebrikizumab Q2W or Q4W, respectively. In the lebrikizumab withdrawal arm only 47.9% maintained their response.⁴ In a further placebo-controlled phase 3 study, in which the effect of lebrikizumab was investigated together with topical corticosteroids, the drug also proved to be clearly superior to placebo.⁵

Dosage: acute flare, short term, long term

The recommended dosage is an induction therapy of 500 mg at week 0 and week 2, followed by 250 mg Q2W until week 16. In patients with an initial partial response, 250 mg Q2W can be continued

until week 24. Once a clinical response is achieved, the recommended maintenance dose of lebrikizumab is 250 mg Q4W.

Safety

Stein Gold et al. investigated the safety of lebrikizumab by analyzing data from eight phase 2 and phase 3 studies. Overall, the frequency of adverse events was comparable between patients receiving lebrikizumab and those given a placebo. Conjunctivitis and AE were the most frequently reported events, with AE reported more frequently in the placebo groups than in the Q2W groups (18.4% versus 6.0%) and conjunctivitis reported more frequently in lebrikizumab in the Q2W groups than in the placebo groups (6.5% versus 1.8%). Nasopharyngitis, headache, allergic conjunctivitis, dry eye, and allergic rhinitis were reported more frequently in the lebrikizumab group.⁶

Simpson et al. reported injection site reactions (1.3%), herpes infection (3.8%), eosinophilia (3.2%) with no associated clinical symptoms, and conjunctivitis (9.6%) as adverse events in patients treated with lebrikizumab.⁷

Notably, based on the currently available clinical trial data lebrikizumab appears to have lower rates of ocular complications than dupilumab. ‘Real world’ comparisons, for instance through national registers, are still awaited.

Monitoring

No biochemical or instrumental exams are reported to be required for the monitoring of the therapy.

Combination with other treatments

Topical corticosteroids can be used in conjunction with lebrikizumab, depending on disease and flare control needs.⁵

References

1. Drucker AM, Lam M, Prieto-Merino D, et al. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Living Systematic Review and Network Meta-Analysis Update. *JAMA Dermatol.* Jul 17 2024;doi:10.1001/jamadermatol.2024.2192
2. Drucker AM, Flohr C, Ellis AG, et al. Systemic immunomodulatory treatments for atopic dermatitis: a living systematic review and network meta-analysis. 18.07.2024, <https://eczematherapies.com/research/>
3. Silverberg JI, Guttman-Yassky E, Thaçi D, et al. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. *N Engl J Med.* Mar 23 2023;388(12):1080-1091. doi:10.1056/NEJMoa2206714
4. Blauvelt A, Thyssen JP, Guttman-Yassky E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. *Br J Dermatol.* May 24 2023;188(6):740-748. doi:10.1093/bjd/ljad022
5. Simpson EL, Gooderham M, Wollenberg A, et al. Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere). *JAMA Dermatol.* Feb 1 2023;159(2):182-191. doi:10.1001/jamadermatol.2022.5534
6. Stein Gold L, Thaçi D, Thyssen JP, et al. Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials. *Am J Clin Dermatol.* Jul 2023;24(4):595-607. doi:10.1007/s40257-023-00792-6
7. Simpson EL, Flohr C, Eichenfield LF, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). *J Am Acad Dermatol.* May 2018;78(5):863-871. doi:10.1016/j.jaad.2018.01.017